Indivior (NASDAQ:INDV) Stock Rating Reaffirmed by Piper Sandler

Indivior (NASDAQ:INDV)‘s stock had its “overweight” rating reissued by stock analysts at Piper Sandler in a report released on Friday, Benzinga reports. They presently have a $15.00 target price on the stock, down from their prior target price of $22.00. Piper Sandler’s price objective would suggest a potential upside of 96.08% from the stock’s current price.

Separately, Craig Hallum cut their target price on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.

Indivior Price Performance

NASDAQ:INDV traded down $0.33 during trading hours on Friday, reaching $7.65. 671,093 shares of the company traded hands, compared to its average volume of 397,913. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The firm’s 50-day moving average is $11.11 and its 200-day moving average is $14.80. The stock has a market cap of $1.05 billion, a P/E ratio of -7.23 and a beta of 0.68. Indivior has a 1-year low of $7.46 and a 1-year high of $23.22.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. The business had revenue of $299.00 million during the quarter, compared to analyst estimates of $285.90 million. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. Equities research analysts expect that Indivior will post 1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indivior

A number of hedge funds have recently made changes to their positions in INDV. Bank of New York Mellon Corp purchased a new stake in Indivior during the 2nd quarter worth $188,000. VELA Investment Management LLC purchased a new stake in shares of Indivior in the second quarter worth about $235,000. XTX Topco Ltd acquired a new stake in shares of Indivior in the second quarter valued at about $249,000. Cubist Systematic Strategies LLC raised its holdings in shares of Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after buying an additional 6,121 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new position in Indivior during the 1st quarter worth approximately $563,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.